A Cross-Sectional Study on Cerebrospinal Fluid Biomarker Levels in Cognitively Normal Elderly Subjects With or Without a Family History of Alzheimer's Disease

CNS Neuroscience and Therapeutics

Volumn 19, Issue 1, 2013, Pages 38-42

  Liu, Zhao ^a   Chen, Huai Hong ^a   Li, Tian Lang ^a   Xu, Lei ^a   Du, Hua Qing ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Amyloid protein; Biomarker; Cerebrospinal fluid; Family history; Late onset Alzheimer's disease

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PROTEIN PHOSPHORYLATION; QUESTIONNAIRE; RISK ASSESSMENT;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FAMILY HEALTH; FEMALE; HUMANS; LINEAR MODELS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; TAU PROTEINS;

EID: 84871359690     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12028     Document Type: Article

References (30)

1. Jack CR Jr. Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology 2012;263:344-361.
2. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351-357.
3. Grønning H, Rahmani A, Gyllenborg J, Dessau RB, Høgh P. Does Alzheimer's disease with early onset progress faster than with late onset? A case-control study of clinical progression and cerebrospinal fluid biomarkers. Dement Geriatr Cogn Disord 2012;33:111-117.
4. Ringman JM, Coppola G, Elashoff D, et al. Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease. Dement Geriatr Cogn Disord 2012;33:1-5.
5. Rosén C, Andreasson U, Mattsson N, et al. Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease. Neuromolecular Med 2012;14:65-73.
6. Parnetti L, Chiasserini D, Eusebi P, et al. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J Alzheimers Dis 2012;29:229-238.
7. Fagan AM, Shaw LM, Xiong C, et al. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol 2011;68:1137-1144.
8. Bakulski KM, Dolinoy DC, Sartor MA, et al. Genome-wide DNA methylation differences between late-onset Alzheimer's disease and cognitively normal controls in human frontal cortex. J Alzheimers Dis 2012;29:571-588.
9. Mosconi L, Mistur R, Glodzik L, et al. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer's. Neurology 2009;72:513-520.
10. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
11. Tiraboschi P, Hansen LA, Alford M, et al. The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology 2000;55:1278-1283.
12. Guo NW, Liu HC, Wong PF, et al. Chinese version and norms of the Mini-Mental State Examination. J Rehabil Med Assoc 1988;16:52-59.
13. Guo NW, Liu HC, Wong PF, et al. Introduction of the Chinese version of the Mini-Mental State Examination. Clin Med Res 1989;23:39-42.
14. Hachinski VC, Iliff LD, Zilhka E. Cerebral blood flow in dementia. Arch Neurol 1975;32:632-637.
15. Almeida OP, Almeida SA. Short versions of the geriatric depression scale: a study of their validity for the diagnosis of a major depressive episode according to ICD-10 and DSM-IV. Int J Geriatr Psychiatry 1999;14:858-865.
16. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Dementia 1982;140:566-572.
17. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 2006;5:655-660.
18. Graff-Radford NR, Lucas JA, Petersen RC, Younkin LH, Younkin SG. P3-011 Analysis of plasma Aβ42 ASA premorbid biomarker for late onset Alzheimer's disease. Neurobiol Aging 2004;25:S354.
19. Ganzer S, Arlt S, Schoder V, et al. CSF-tau, CSF-Abeta1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity. J Neural Transm 2003;110:1149-1160.
20. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007;8:101-112.
21. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443:787-795.
22. Castellani RJ, Moreira PI, Perry G, Zhu X. The role of iron as a mediator of oxidative stress in Alzheimer disease. BioFactors 2012;38:133-138.
23. Butterfield DA. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res 2002;36:1307-1313.
24. Mohmmad Abdul H, Sultana R, Keller JN, St Clair DK, Markesbery WR, Butterfield DA. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease. J Neurochem 2006;96:1322-1335.
25. Pensalfini A, Zampagni M, Liguri G, et al. Membrane cholesterol enrichment prevents Aβ-induced oxidative stress in Alzheimer's fibroblasts. Neurobiol Aging 2011;32:210-222.
26. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;8:119-128.
27. Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord 2003;15:169-176.
28. Yates PA, Sirisriro R, Villemagne VL, et al. Cerebral microhemorrhage and brain β-amyloid in aging and Alzheimer disease. Neurology 2011;77:48-54.
29. Kasuga K, Tokutake T, Ishikawa A, et al. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2010;81:608-610.
30. Boche D, Denham N, Holmes C, Nicoll JA. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol 2010;120:369-384.